← All stocks

Mineralys Therapeutics, Inc.

MLYS Scheduled selling only

CIK 0001933414 #1952 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$193.19K

$0.00 on a plan · $193.19K straight out of an exercise

Sold at will

$0.00

0 of 1 sales

Net

−$193.19K

$0.00 against sales at will

By person

13 insiders · 1 transaction

24.6×

Jon Congleton holds 24.6 times base salary in stock. $15.68M of shares against $636.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Jon Congleton last reported holding, valued at $25.98, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Warren Eric

Chief Commercial Officer

—

$193.19K (1) scheduled

−$193.19K

38,400

0.0434%

$997.51K

0.0%

Slingsby Brian Taylor

Director

—

7,910,038

8.95%

$205.48M

−8.5%

RA CAPITAL MANAGEMENT, L.P. entity

Director

—

5,825,521

6.59%

$151.33M

+95.6%

Samsara BioCapital GP, LLC entity

10% owner

—

5,674,916

6.42%

$147.42M

+11.8%

Congleton Jon

Chief Executive Officer

—

603,621

0.6828%

$15.68M

−33.8%

AKKARAJU SRINIVAS

Director

—

594,435

0.6724%

$15.44M

—

Ferguson James J. III

Chief Medical Officer

—

102,400

0.1158%

$2.66M

—

Rodman David Malcom

Chief Medical Officer

—

51,384

0.0581%

$1.33M

−60.2%

Levy Adam Scott

CFO and Secretary

—

48,538

0.0549%

$1.26M

−69.8%

Karydas Daphne

Director

—

6,200

0.0070%

$161.06K

—

SBLENDORIO GLENN

Director

—

6,200

0.0070%

$161.06K

—

Gold Alexander M

Director

—

6,200

0.0070%

$161.06K

—

DiRocco Derek

Director

—

6,200

0.0070%

$161.06K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Warren Eric

21 Aug 2026

Chief Commercial Officer

Sold after exercise

7,437

$25.98

$193.19K

Show all 1 transactions →

What was left out

Form 4 filings counted 1

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 1

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 7,437

History held since 13 Feb 2023